Venrock Adviser, LLC

Position in DNTH — Dianthus Therapeutics, Inc. /DE/

CIK 1615982 NEW YORK, NY

Position in DNTH

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$99,025,600

+$57,815,600 QoQ

Shares Held

1,180,000

+18.0% QoQ

Ownership

2.16%

of shares outstanding

% of Portfolio

3.70%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. DNTH ranks #6 (3.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	8,493,321	$714,882,828
2	ERAS	Erasca, Inc.	16,382,812	$265,073,898
3	ORKA	Oruka Therapeutics, Inc.	4,148,428	$203,480,393
4	SYRE	Spyre Therapeutics, Inc.	3,685,448	$185,893,997
5	KALV	KalVista Pharmaceuticals, Inc.	6,474,485	$130,331,383
6	DNTH	Dianthus Therapeutics, Inc. /DE/ This page	1,180,000	$99,025,600
7	DMRA	Damora Therapeutics, Inc.	3,603,595	$93,333,110
8	OCUL	Ocular Therapeutix, Inc	10,346,926	$87,638,463

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$99,025,600	1,180,000	+18.0%	Shares	Sole	2026-05-15
2025-12-31	$41,210,000	1,000,000	+4.1%	Shares	Sole	2026-02-17
2025-09-30	$37,807,598	960,803	-3.9%	Shares	Sole	2025-11-14
2025-06-30	$18,630,000	1,000,000	-42.7%	Shares	Sole	2025-08-14
2025-03-31	$31,642,926	1,744,373	0.0%	Shares	Sole	2025-05-15
2024-12-31	$38,027,331	1,744,373	0.0%	Shares	Sole	2025-02-14
2024-09-30	$47,760,932	1,744,373	-16.7%	Shares	Sole	2024-11-14
2024-06-30	$54,202,373	2,094,373	0.0%	Shares	Sole	2024-08-14
2024-03-31	$62,831,190	2,094,373	+125.8%	Shares	Sole	2024-05-15
2023-12-31	$9,648,142	927,706	0.0%	Shares	Sole	2024-02-14
2023-09-30	$12,681,741	927,706	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.